These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23716303)

  • 1. New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.
    Takahashi T; Serada S; Ako M; Fujimoto M; Miyazaki Y; Nakatsuka R; Ikezoe T; Yokoyama A; Taguchi T; Shimada K; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Mori M; Doki Y; Naka T; Nishida T
    Int J Cancer; 2013 Dec; 133(11):2737-43. PubMed ID: 23716303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells.
    Thao le B; Vu HA; Yasuda K; Taniguchi S; Yagasaki F; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Apr; 8(8):683-8. PubMed ID: 19417561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
    Sakurama K; Noma K; Takaoka M; Tomono Y; Watanabe N; Hatakeyama S; Ohmori O; Hirota S; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tanaka N; Naomoto Y
    Mol Cancer Ther; 2009 Jan; 8(1):127-34. PubMed ID: 19139121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOCS1 gene therapy has antitumor effects in imatinib-resistant gastrointestinal stromal tumor cells through FAK/PI3 K signaling.
    Sugase T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hiramatsu K; Nishida T; Hirota S; Saito Y; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Hanasaki K; Kishimoto T; Mori M; Doki Y; Naka T
    Gastric Cancer; 2018 Nov; 21(6):968-976. PubMed ID: 29623544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.
    Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB
    Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
    Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
    Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
    Antonescu CR; Besmer P; Guo T; Arkun K; Hom G; Koryotowski B; Leversha MA; Jeffrey PD; Desantis D; Singer S; Brennan MF; Maki RG; DeMatteo RP
    Clin Cancer Res; 2005 Jun; 11(11):4182-90. PubMed ID: 15930355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance.
    Javidi-Sharifi N; Traer E; Martinez J; Gupta A; Taguchi T; Dunlap J; Heinrich MC; Corless CL; Rubin BP; Druker BJ; Tyner JW
    Cancer Res; 2015 Mar; 75(5):880-91. PubMed ID: 25432174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
    Gordon PM; Fisher DE
    J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
    Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
    Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Green tea (-)-epigalocatechin-3-gallate inhibits KIT activity and causes caspase-dependent cell death in gastrointestinal stromal tumor including imatinib-resistant cells.
    Chi HT; Vu HA; Iwasaki R; Thao le B; Hara Y; Taguchi T; Watanabe T; Sato Y
    Cancer Biol Ther; 2009 Oct; 8(20):1934-9. PubMed ID: 19770581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression.
    Tu Y; Zuo R; Ni N; Eilers G; Wu D; Pei Y; Nie Z; Wu Y; Wu Y; Ou WB
    Cell Cycle; 2018; 17(23):2577-2592. PubMed ID: 30488756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular concentration of the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumor cells.
    Berglund E; Ubhayasekera SJ; Karlsson F; Akcakaya P; Aluthgedara W; Ahlen J; Fröbom R; Nilsson IL; Lui WO; Larsson C; Zedenius J; Bergquist J; Bränström R
    Anticancer Drugs; 2014 Apr; 25(4):415-22. PubMed ID: 24361761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
    Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis.
    Nagata K; Kawakami T; Kurata Y; Kimura Y; Suzuki Y; Nagata T; Sakuma Y; Miyagi Y; Hirano H
    J Proteomics; 2015 Feb; 115():132-42. PubMed ID: 25554490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor.
    Rossi F; Ehlers I; Agosti V; Socci ND; Viale A; Sommer G; Yozgat Y; Manova K; Antonescu CR; Besmer P
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12843-8. PubMed ID: 16908864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Zheng S; Pan YL; Tao DY; Wang JL; Huang KE
    Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
    Gao X; Xue A; Fang Y; Shu P; Ling J; Hou Y; Shen K; Qin J; Sun Y; Qin X
    Oncotarget; 2016 Mar; 7(12):14300-9. PubMed ID: 26893362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors.
    Li F; Huynh H; Li X; Ruddy DA; Wang Y; Ong R; Chow P; Qiu S; Tam A; Rakiec DP; Schlegel R; Monahan JE; Huang A
    Cancer Discov; 2015 Apr; 5(4):438-51. PubMed ID: 25673643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.